Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
04 April 2024
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
04 April 2024
GenSight Biologics Announces Its 2024 Financial Calendar
22 March 2024
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
20 March 2024
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
12 March 2024
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
06 March 2024
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
04 March 2024
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
08 February 2024
GenSight Biologics announces completion of a €5 million capital increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital
25 January 2024
GenSight Biologics Reports Cash Position as of December 31, 2023, and Provides Business Update
16 January 2024
Laurence Rodriguez, appointed CEO of GenSight Biologics in December 2023, joins the Company’s Board of Directors
View previous 9 articles
1
2
3
4
5
6
7
…
24
View next 9 articles
Go back to the page of the page